Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News PerkinElmer and Transgenomic to commercialise oncology tests

PerkinElmer and Transgenomic to commercialise oncology tests

4th November 2013

PerkinElmer has announced a new collaboration agreement with Transgenomic in the field of personalised oncology treatment, effective as of January 1st 2014.

The alliance will see the companies working together to market and distribute Transgenomic's oncology diagnostic test portfolio of products in territories outside the US, with PerkinElmer gaining non-exclusive rights to begin sales, marketing, distribution and field service activities worldwide.

It covers molecular diagnostic oncology products including the CRC RAScan and ACE kits, for use on the PerkinElmer LabChip MultiDx platform, with initial launches set to take place in Europe.

This partnership will leverage Transgenomic's technical and scientific expertise in this field and PerkinElmer's strong global reach and operational capabilities.

Steve Wallace, vice-president for molecular diagnostics at PerkinElmer, said: "We look forward to providing customers a complete testing solution including DNA extraction, oncology diagnostic assays and high-performance microfluidics instrumentation."

Last week, the firm announced its financial results for the third quarter of 2013, during which it experienced year-on-year revenue growth of three percent.ADNFCR-8000103-ID-801656699-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.